Latest News

Oslo, Norway, 3 March 2021: Photocure ASA (OSE:PHO) reports Hexvix^®/Cysview^® revenues of NOK 97.7 million in the fourth quarter of 2020 (Q4 2019: NOK 58.8). Product revenues increased 20% in FY2020 representing strong execution in an unprecedented year. Due to the ongoing pandemic, the Company suspends guidance for its 2023 revenue ambition in the range of NOK 1 billion. Photocure plans to re-issue financial guidance once the impact from Covid-19 is significantly diminished and physician practices and patient flow have normalized in both the U.S. and Europe.

Oslo, Norway, 24 February 2021: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2020 financial results on Wednesday 3 March 2021 at 07:00 CET and invites investors, analysts and the media to a presentation at 14:00 CET the same day.

A new study in Germany based on real life claims data compares costs of initial TURBT in bladder cancer treatment using standard white light- vs. blue light-TURBT* in 4500+ patients.

Agreement Expands Photocure’s Hexvix^®/Cysview^® Franchise Footprint to over 30 Countries

Oslo, Norway January 26, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients,  announces that it has entered into a partnership agreement with Asieris MediTech Co., Ltd. (Asieris), a division of Jiangsu Yahong Meditech Co., Ltd., whereby Asieris has obtained exclusive rights to register and commercialize Hexvix^® in Mainland China and Taiwan.
 

*Number of shares following registration of share issue is corrected

Oslo, Norway, 15 December 2020: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 3 December 2020 regarding registration of a share capital increase following the exercise of share options.

PRESS RELEASE – Oslo, Norway, 7 December, 2020: Photocure ASA (OSE:PHO) today announced new data and analyses presented at the 21^st Annual Meeting of the Society of Urologic Oncology (SUO). Presentations discussed the use of Blue Light Cystoscopy (BLC™) with Cysview^®, in particular the positive impact on patient outcomes in the surveillance setting without a significant impact on the cost of care, as well as the benefits of identifying early recurrences in high-risk NMIBC patients undergoing BCG treatment.

Oslo, Norway, 3 December 2020: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 1 December 2020 regarding a share capital increase following the exercise of share options.

Oslo, Norway, 1 December 2020: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 30 November 2020 regarding exercise of share options.

Oslo, Norway, 30 November 2020: Participants in Photocure ASA's ("Photocure" or the "Company") share option program have on 30 November 2020 exercised a total of 90,150 options distributed as follows:

Oslo, Norway, 11 November, 2020: Photocure ASA (OSE:PHO) today announces that its partner Asieris Pharmaceuticals has initiated the phase III clinical trial for APL-1702 (Cevira^®), triggering a USD 1.5 million milestone payment under the global licensing deal.

Oslo, Norway, 10 November 2020: Photocure ASA (OSE:PHO) today reported Hexvix^®/Cysview^® revenues of NOK 49.6 million in the third quarter of 2020 (Q3 2019: NOK 51.1), with the U.S. market continuing the Covid-19 rebound with a growth of 20%. Photocure has successfully launched the European Hexvix operations and reiterates the strong outlook and 2023 ambitions.

Oslo, Norway, 4 November 2020: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2020 financial results on Tuesday 10 November 2020 at 07:00 CET and invites investors, analysts and the media to a presentation at 14:00 CET the same day.

PRESS RELEASE – Oslo, Norway, 16 October, 2020: Photocure ASA (OSE:PHO) today announces a highlight from the BLADDR 2020 congress, a poster presentation on new findings from the Nordic Flexible BLC registry, an ongoing prospective multicenter study. It demonstrates that flexible Blue Light Cystoscopy helped resolve a substantial amount of cases by complete removal on-site or direct referral to intravesical treatment, providing increased efficacy to manage non-muscle-invasive bladder cancer (NMIBC) in the office setting.

Oslo, Norway, 5 October 2020: Photocure ASA (OSE:PHO) today announces that the European Patent Office (EPO) has granted patent EP 2983780 covering the commercial Cevira^® device in Europe until 2034.

Oslo, Norway, 1 October 2020: Photocure ASA (OSE:PHO) today announces the commencement of the sales, marketing and distribution of Hexvix^® in the European markets formerly operated by Ipsen Pharma SAS (Ipsen). The successful transition and launch of European Hexvix operations creates a robust platform for accelerated growth and expansion for Photocure.

Oslo, Norway, 15 September 2020 - The board of directors in Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.

Oslo, Norway, 3 September 2020: Reference is made to the stock exchange announcement by Photocure ASA ("Photocure") published 31 August 2020 regarding a share capital increase following the exercise of employee share options.

Oslo, Norway, 31 August 2020.

Participants in Photocure ASA's ("Photocure") share option program have on 31 August 2020 exercised a total of 17,366 options, distributed as follows:

Photocure's CEO Dan Schneider and CFO Erik Dahl will continue their dialogue with stakeholders at a live Q&A session on Wednesday, August 26, 2020, organized by Xtrainvestor on their facebook channel.